MarkToddLeibowitzMD

PubMed

• 6 citations
  Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing.
  Peter R. Bieck, Mark Leibowitz, D. Richard Lachno, Edouard Ledent, Robert Padich, Stan S. Jhee> ;Journal of Clinical Psychopharmacology. 2016 Dec 1
• 2 citations
  The effect of naltrexone on sleep parameters in healthy male volunteers.
  John J. Sramek, James M. Andry, Hong Ding, Henry Riordan, Mark Leibowitz, Neal R. Cutler> ;Journal of Clinical Psychopharmacology. 2014 Feb 1
• 48 citations
  Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moder...
  Carol Addy, Chris Assaid, David Hreniuk, Mark Stroh, Yang Xu, W. Joseph Herring, Aaron Ellenbogen, H. A. Jinnah, Louis Kirby, Mark Leibowitz, R. Malcolm Stewart, Danie...> ;Journal of Clinical Pharmacology. 2009 Jul 1
• 16 citations
  Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects.
  Stan S. Jhee, William Lyness, Patrick B. Rojas, Mark Leibowitz, Victoria Zarotsky, Lisbeth V. Jacobsen> ;Journal of Clinical Pharmacology. 2004 Mar 1
• Long-term treatment with pergolide: decreased efficacy with time.
  Lieberman AN, Goldstein M, Leibowitz M, Gopinathan G, Neophytides A, Hiesiger E, Nelson J, Walker R> ;Neurology. 1984-02-01
• Further studies with pergolide in Parkinson disease.
  Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Neophytides A, Walker R, Hiesiger E, Nelson J> ;Neurology. 1982-10-01
• The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
  Lieberman AN, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Walker R, Pact V> ;Clin. Pharmacol. Ther.. 1982-07-01
• Cardiac effects of pergolide.
  Leibowitz M, Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Gopinathan G, Mehl S> ;Clin. Pharmacol. Ther.. 1981-12-01
• Lisuride combined with levodopa in advanced Parkinson disease.
  Lieberman AN, Goldstein M, Leibowitz M, Neophytides A, Gopinathan G, Walker R, Pact V> ;Neurology. 1981-11-01
• Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
  Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, Kleinberg D> ;Neurology. 1981-08-01
• Treatment of advanced Parkinson disease with pergolide.
  Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Kleinberg D> ;Neurology. 1981-06-01
• Long-term hypnotic efficacy and safety of triazolam and flurazepam.
  Leibowitz M, Sunshine A> ;J Clin Pharmacol. 1978-01-01
• Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.
  Kompoliti, K., Adler, C. H., Raman, R., Pincus, J. H., Leibowitz, M. T., Ferry, J. J., Blasucci, L., Caviness, J. N., Leurgans, S., Chase, W. M., Yones, L. C., Tan, E....> ;Neurology. 2002 May 14
• Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double...
  Sramek, J. J., Leibowitz, M. T., Weinstein, S. P., Rowe, E. D., Mendel, C. M., Levy, B., McMahon, F. G., Mullican, W. S., Toth, P. D., Cutler, N. R.> ;J Hum Hypertens. 2002 Jan
• Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
  Lefèvre, G., Sedek, G., Jhee, S. S., Leibowitz, M. T., Huang, H. L., Enz, A., Maton, S., Ereshefsky, L., Pommier, F., Schmidli, H., Appel-Dingemanse, S.> ;Clin Pharmacol Ther. 2008 Jan
• Join now to see all